Zazeri G, Povinelli A, Bertozo L, Jones A, Ximenes V
Int J Mol Sci. 2024; 25(23).
PMID: 39684376
PMC: 11640942.
DOI: 10.3390/ijms252312664.
Yokoyama T, Fujii S, Ostermann A, Schrader T, Nabeshima Y, Mizuguchi M
IUCrJ. 2022; 9(Pt 5):562-572.
PMID: 36071806
PMC: 9438496.
DOI: 10.1107/S2052252522006297.
Moll A, Ramirez L, Ninov M, Schwarz J, Urlaub H, Zweckstetter M
Nat Commun. 2022; 13(1):3668.
PMID: 35760815
PMC: 9237115.
DOI: 10.1038/s41467-022-31396-z.
Povinelli A, Zazeri G, Jones A, Cornelio M
Pharmaceuticals (Basel). 2021; 14(12).
PMID: 34959698
PMC: 8703466.
DOI: 10.3390/ph14121298.
Zazeri G, Povinelli A, Lima M, Cornelio M
Biomedicines. 2020; 8(12).
PMID: 33353024
PMC: 7766160.
DOI: 10.3390/biomedicines8120629.
Solution structure of the Hop TPR2A domain and investigation of target druggability by NMR, biochemical and in silico approaches.
Darby J, Vidler L, Simpson P, Al-Lazikani B, Matthews S, Sharp S
Sci Rep. 2020; 10(1):16000.
PMID: 32994435
PMC: 7524759.
DOI: 10.1038/s41598-020-71969-w.
Coupling of HSP72 α-Helix Subdomains by the Unexpected Irreversible Targeting of Lysine-56 over Cysteine-17; Coevolution of Covalent Bonding.
Aljoundi A, El Rashedy A, Appiah-Kubi P, Soliman M
Molecules. 2020; 25(18).
PMID: 32947765
PMC: 7570744.
DOI: 10.3390/molecules25184239.
HSP70 Multi-Functionality in Cancer.
Albakova Z, Armeev G, Kanevskiy L, Kovalenko E, Sapozhnikov A
Cells. 2020; 9(3).
PMID: 32121660
PMC: 7140411.
DOI: 10.3390/cells9030587.
Kinetic Optimization of Lysine-Targeting Covalent Inhibitors of HSP72.
Pettinger J, Carter M, Jones K, Cheeseman M
J Med Chem. 2019; 62(24):11383-11398.
PMID: 31725295
PMC: 6959841.
DOI: 10.1021/acs.jmedchem.9b01709.
Combination of Anti-Cancer Drugs with Molecular Chaperone Inhibitors.
Shevtsov M, Multhoff G, Mikhaylova E, Shibata A, Guzhova I, Margulis B
Int J Mol Sci. 2019; 20(21).
PMID: 31652993
PMC: 6862641.
DOI: 10.3390/ijms20215284.
Targeting Translation Activity at the Ribosome Interface with UV-Active Small Molecules.
Kandala D, Del Piano A, Minati L, Clamer M
ACS Omega. 2019; 4(6):10336-10345.
PMID: 31460127
PMC: 6648492.
DOI: 10.1021/acsomega.9b00366.
Large-scale crystallization and neutron crystallographic analysis of HSP70 in complex with ADP.
Yokoyama T, Ostermann A, Schrader T, Mizuguchi M
Acta Crystallogr F Struct Biol Commun. 2017; 73(Pt 10):555-559.
PMID: 28994403
PMC: 5633922.
DOI: 10.1107/S2053230X1701264X.
Pyrrolo[2,3-d]pyrimidine (7-deazapurine) as a privileged scaffold in design of antitumor and antiviral nucleosides.
Perlikova P, Hocek M
Med Res Rev. 2017; 37(6):1429-1460.
PMID: 28834581
PMC: 5656927.
DOI: 10.1002/med.21465.
Targeting secondary protein complexes in drug discovery: studying the druggability and chemical biology of the HSP70/BAG1 complex.
Evans L, Jones K, Cheeseman M
Chem Commun (Camb). 2017; 53(37):5167-5170.
PMID: 28439591
PMC: 5708526.
DOI: 10.1039/c7cc01376k.
An Irreversible Inhibitor of HSP72 that Unexpectedly Targets Lysine-56.
Pettinger J, Le Bihan Y, Widya M, van Montfort R, Jones K, Cheeseman M
Angew Chem Int Ed Engl. 2017; 56(13):3536-3540.
PMID: 28225177
PMC: 5412842.
DOI: 10.1002/anie.201611907.
The remarkable multivalency of the Hsp70 chaperones.
Zuiderweg E, Hightower L, Gestwicki J
Cell Stress Chaperones. 2017; 22(2):173-189.
PMID: 28220454
PMC: 5352603.
DOI: 10.1007/s12192-017-0776-y.
A fragment-based approach applied to a highly flexible target: Insights and challenges towards the inhibition of HSP70 isoforms.
Jones A, Westwood I, Osborne J, Matthews T, Cheeseman M, Rowlands M
Sci Rep. 2016; 6:34701.
PMID: 27708405
PMC: 5052559.
DOI: 10.1038/srep34701.